These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

137 related articles for article (PubMed ID: 3157546)

  • 1. Long-term effects of Depo-Provera on carbohydrate and lipid metabolism.
    Liew DF; Ng CS; Yong YM; Ratnam SS
    Contraception; 1985 Jan; 31(1):51-64. PubMed ID: 3157546
    [TBL] [Abstract][Full Text] [Related]  

  • 2. A comparative study of the metabolic effects of injectable and oral contraceptives.
    Liew DF; Ng CS; Heng SH; Ratnam SS
    Contraception; 1986 Apr; 33(4):385-94. PubMed ID: 2942334
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Alterations in blood lipids and side effects induced by depo-provera in Nigerian women.
    Fajumi JO
    Contraception; 1983 Feb; 27(2):161-75. PubMed ID: 6221882
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Forearm bone density in users of Depo-Provera as a contraceptive method.
    Bahamondes L; Perrotti M; Castro S; Faúndes D; Petta C; Bedone A
    Fertil Steril; 1999 May; 71(5):849-52. PubMed ID: 10231044
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Depo Provera: still controversial.
    Wren LM
    Int Health News; 1988 Feb; 9(2):2-3, 8. PubMed ID: 12179873
    [TBL] [Abstract][Full Text] [Related]  

  • 6. A prospective comparison of bone density in adolescent girls receiving depot medroxyprogesterone acetate (Depo-Provera), levonorgestrel (Norplant), or oral contraceptives.
    Cromer BA; Blair JM; Mahan JD; Zibners L; Naumovski Z
    J Pediatr; 1996 Nov; 129(5):671-6. PubMed ID: 8917232
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Effect of depo-medroxyprogesterone acetate on coagulation factors and serum lipids in Egyptian women.
    Fahmy K; Khairy M; Allam G; Gobran F; Alloush M
    Contraception; 1991 Oct; 44(4):431-44. PubMed ID: 1836755
    [TBL] [Abstract][Full Text] [Related]  

  • 8. A case for concern?
    Gartland A
    Nurs Times; 1983 May 4-10; 79(18):10-1. PubMed ID: 6222288
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Depo-Provera: a critical analysis.
    Minkin S
    Women Health; 1980; 5(2):49-69. PubMed ID: 6451987
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Hormonal contraceptives and carbohydrate tolerance. II. Influence of medroxyprogesterone acetate and chronic oral contraceptives.
    Vermeulen A; Thiery M
    Diabetologia; 1974 Aug; 10(4):253-9. PubMed ID: 4213146
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Pharmacokinetic study of different doses of Depo Provera.
    Fotherby K; Koetsawang S; Mathrubutham M
    Contraception; 1980 Nov; 22(5):527-36. PubMed ID: 6451351
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Timing of onset of contraceptive effectiveness in Depo-Provera users: Part I. Changes in cervical mucus.
    Petta CA; Faundes A; Dunson TR; Ramos M; DeLucio M; Faundes D; Bahamondes L
    Fertil Steril; 1998 Feb; 69(2):252-7. PubMed ID: 9496338
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Effect of long-term hormonal contraception on plasma lipids.
    Deslypere JP; Thiery M; Vermeulen A
    Contraception; 1985 Jun; 31(6):633-42. PubMed ID: 4042661
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Depo-Provera--ethical issues in its testing and distribution.
    Potts M; Paxman JM
    J Med Ethics; 1984 Mar; 10(1):9-20. PubMed ID: 6231379
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Drug regulation in the United States and the United Kingdom: the Depo-Provera story.
    Richard BW; Lasagna L
    Ann Intern Med; 1987 Jun; 106(6):886-91. PubMed ID: 2953290
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Long-term effects of depot-medroxyprogesterone acetate on lipoprotein metabolism.
    Garza-Flores J; De la Cruz DL; Valles de Bourges V; Sanchez-Nuncio R; Martinez M; Fuziwara JL; Pérez-Palacios G
    Contraception; 1991 Jul; 44(1):61-71. PubMed ID: 1832626
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Plasma levels of medroxyprogesterone acetate (MPA), sex-hormone binding globulin, gonadal steroids, gonadotrophins and prolactin in women during long-term use of depo-MPA (Depo-Provera) as a contraceptive agent.
    Jeppsson S; Gershagen S; Johansson ED; Rannevik G
    Acta Endocrinol (Copenh); 1982 Mar; 99(3):339-43. PubMed ID: 6461995
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Return of fertility after discontinuation of depot medroxyprogesterone acetate and intra-uterine devices in Northern Thailand.
    Pardthaisong T; Gray RH; McDaniel EB
    Lancet; 1980 Mar; 1(8167):509-12. PubMed ID: 6102234
    [TBL] [Abstract][Full Text] [Related]  

  • 19. The long-term growth and development of children exposed to Depo-Provera during pregnancy or lactation.
    Pardthaisong T; Yenchit C; Gray R
    Contraception; 1992 Apr; 45(4):313-24. PubMed ID: 1387602
    [TBL] [Abstract][Full Text] [Related]  

  • 20. In utero exposure to steroid contraceptives and outcome of pregnancy.
    Pardthaisong T; Gray RH
    Am J Epidemiol; 1991 Oct; 134(8):795-803. PubMed ID: 1835282
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.